A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered by intravenous (IV) infusion in participants with relapsed or refractory B-cell NHL. This entry-to-human study consists of 2 parts: a dose escalation part (Phase I) and an expansion part (Phase Ⅱ)

Trial Details

NCT ID
NCT05806099
Phase
PHASE1 / PHASE2
Sponsor
Beijing Mabworks Biotech Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • MBS303
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Able and willing to provide written informed consent and to comply with the study protocol.
  • Adult patients, ≥18 years of age;
  • CD20+ B-cell Non-Hodgkin Lymphoma who have relapsed after or failed to respond to at least one prior treatment regimen with an anti-CD20 monoclonal…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →